F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
about
The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer.Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer.Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients.68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer.Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer.Current status of theranostics in prostate cancer.Radiotheranostics in Cancer Diagnosis and Management.Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study.A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T.PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007.Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and ChallengesRole of PET imaging for biochemical recurrence following primary treatment for prostate cancerKeeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents
P2860
Q38720852-79E7F2C6-1D78-42F0-BFD5-FA3323292953Q41683899-5154490B-2E9E-4541-82F3-CD332713A0B9Q47109640-B1FC6D2F-2FF4-421A-A33A-A25990C15797Q47147617-E0F13BDC-C240-4688-B46F-7282B3B60191Q47156816-88DE2302-D20A-4232-A433-8BE6242975A5Q47241139-17DFF925-A7B2-4C01-BFE1-38D3A4CD395FQ47719762-17A1601D-5DD2-49FC-A8EC-5AFA8DFBAB30Q47731005-26571FE3-8075-4F11-A9B5-2BCFFB28206FQ47779789-8306B478-F1AE-497B-8BFD-20A217DBBF8BQ47963642-08B76021-14CB-4E1B-95EC-3E546F31ED97Q48141689-ACD8720A-EC47-4656-A81D-9EE23BAF5AE7Q48221776-51AD7DFA-D07F-4054-A85E-D17A3AFE03A8Q48297324-26F6AB2C-EDC5-4E0E-8812-DD179A59D490Q50034009-A145ED21-F59B-43E3-B7AF-EA7F33084CD6Q52590598-7755A95D-0E2F-4E5F-B3B8-964093855326Q57107208-E57546F9-5159-478B-AFAA-4515C1467DC1Q58562169-66262312-B368-488D-A88C-A98C9A732CF5Q59130960-756F8186-E5BE-4D96-A6FA-56B4FE3F7C69
P2860
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
F-18 labelled PSMA-1007: biodi ...... s in prostate cancer patients.
@en
F-18 labelled PSMA-1007: biodi ...... s in prostate cancer patients.
@nl
type
label
F-18 labelled PSMA-1007: biodi ...... s in prostate cancer patients.
@en
F-18 labelled PSMA-1007: biodi ...... s in prostate cancer patients.
@nl
prefLabel
F-18 labelled PSMA-1007: biodi ...... s in prostate cancer patients.
@en
F-18 labelled PSMA-1007: biodi ...... s in prostate cancer patients.
@nl
P2093
P2860
P50
P1476
F-18 labelled PSMA-1007: biodi ...... s in prostate cancer patients.
@en
P2093
C Kratochwil
Frederik L Giesel
M Vinsensia
S Duensing
U Haberkorn
P2860
P2888
P304
P356
10.1007/S00259-016-3573-4
P577
2016-11-26T00:00:00Z